Navigation Links
Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
Date:10/29/2010

CRANBURY, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will host a live conference call and webcast today, October 29, 2010 at 8:30 a.m. Eastern Time to discuss the Company's exclusive worldwide agreement with GlaxoSmithKline PLC to develop and commercialize Amigal (migalastat HCl) for the treatment of Fabry disease.

Interested participants and investors may access the conference call today at 8:30 a.m. Eastern Time by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international). A telephonic replay of the call will be available for seven days beginning at 8 p.m. Eastern Time. Access numbers for this replay are 800-642-1687 (U.S./Canada) and 706-645-9291 (international); participant code 20951935.

A live audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, an audio webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 30 days.

Amicus' press releases are available at www.amicustherapeutics.com.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases.  The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and CNS diseases.  Amicus' lead program is in Phase 3 for the treatment of Fabry disease.

FOLD -G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
2. Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
3. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
4. Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
5. Amicus Therapeutics to Host its First Quarter 2010 Financial Results Conference Call and Webcast on May 6, 2010
6. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
7. Amicus Therapeutics Announces Closing of $18.5 Million Registered Direct Offering of Common Stock
8. Amicus Therapeutics Announces $18.5 Million Registered Direct Offering of Common Stock
9. Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements
10. Amicus Therapeutics Presents Positive Data Update From Phase 2 Extension Study of Amigal(TM) for Fabry Disease
11. Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:10/2/2017)... Oct. 2, 2017 Halo Labs announces the European launch ... called the HORIZON at MIBio 2017 in Cambridge, U.K ... visible particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity ... novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... LOS ANGELES (PRWEB) , ... October 12, 2017 ... ... of Parsa Mohebi Hair Restoration, has recently contributed a medical article to the ... doctors, on cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):